TY - JOUR
T1 - Effect of luteal-phase support on endometrial L-selectin ligand expression after recombinant follicle-stimulating hormone and ganirelix acetate for in vitro fertilization
AU - Vlahos, Nikos F.
AU - Lipari, Christopher W.
AU - Bankowski, Brandon
AU - Lai, Tsung Hsuan
AU - King, Jeremy A.
AU - Shih, Ie Ming
AU - Fragakis, Konstantine
AU - Zhao, Yulian
N1 - Funding Information:
This work was supported by a research grant from Akzo Nobel Inc.
PY - 2006/10
Y1 - 2006/10
N2 - Context: The impact of different types of luteal phase support on endometrial receptivity after ovarian stimulation has not been investigated. Objective: Our objective was to evaluate the impact of different luteal-phase support protocols on sex steroid levels and on endometrial expression of L-selectin ligand after ovarian hyperstimulation with a GnRH antagonist protocol. Patients and Design: Seventeen oocyte donors who underwent ovarian stimulation with a recombinant FSH/ganirelix acetate protocol were randomized into three groups: group I had no luteal-phase support; group II had luteal support with micronized progesterone; and group III had luteal support with progesterone plus 17β-estradiol. All donors had endometrial biopsies on the day of retrieval, and then 3, 5, and 10 d after retrieval. In addition, they had serum estradiol and progesterone measurements on d 3, 5, and 10. Main Outcome Measures: Endometrial L-selectin ligand expression was detected by immunohistochemical staining in the luminal and glandular epithelium. A histological score was used for the quantification of the immunostaining. Sex steroid levels were measured during the luteal phase. Results: By d 10 after retrieval, there was a significant decrease in mean progesterone levels in group I compared with the other two groups that may reflect the expected demise of the corpus luteum. There was also a significant increase in the presence of L-selectin ligands in the luminal epithelium in group III. Conclusions: During controlled ovarian stimulation with a GnRH antagonist protocol, luteal-phase support with micronized progesterone and 17β-estradiol seem to increase endometrial L-selectin ligand expression in the luminal endothelium.
AB - Context: The impact of different types of luteal phase support on endometrial receptivity after ovarian stimulation has not been investigated. Objective: Our objective was to evaluate the impact of different luteal-phase support protocols on sex steroid levels and on endometrial expression of L-selectin ligand after ovarian hyperstimulation with a GnRH antagonist protocol. Patients and Design: Seventeen oocyte donors who underwent ovarian stimulation with a recombinant FSH/ganirelix acetate protocol were randomized into three groups: group I had no luteal-phase support; group II had luteal support with micronized progesterone; and group III had luteal support with progesterone plus 17β-estradiol. All donors had endometrial biopsies on the day of retrieval, and then 3, 5, and 10 d after retrieval. In addition, they had serum estradiol and progesterone measurements on d 3, 5, and 10. Main Outcome Measures: Endometrial L-selectin ligand expression was detected by immunohistochemical staining in the luminal and glandular epithelium. A histological score was used for the quantification of the immunostaining. Sex steroid levels were measured during the luteal phase. Results: By d 10 after retrieval, there was a significant decrease in mean progesterone levels in group I compared with the other two groups that may reflect the expected demise of the corpus luteum. There was also a significant increase in the presence of L-selectin ligands in the luminal epithelium in group III. Conclusions: During controlled ovarian stimulation with a GnRH antagonist protocol, luteal-phase support with micronized progesterone and 17β-estradiol seem to increase endometrial L-selectin ligand expression in the luminal endothelium.
UR - http://www.scopus.com/inward/record.url?scp=33749638777&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33749638777&partnerID=8YFLogxK
U2 - 10.1210/jc.2006-0520
DO - 10.1210/jc.2006-0520
M3 - Article
C2 - 16868054
AN - SCOPUS:33749638777
SN - 0021-972X
VL - 91
SP - 4043
EP - 4049
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 10
ER -